Arrowstreet Capital’s Denali Therapeutics DNLI Stock Holding History

Arrowstreet Capital’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-18,725	Closed	-$575K	–	1356
2022 Q3	$575K	Buy	+18,725	New	+$609K	﹤0.01%	1086
2021 Q4	–	Sell	-96,868	Closed	-$4.89M	–	1497
2021 Q3	$4.89M	Buy	+96,868	New	+$5.46M	0.01%	946
2021 Q2	–	Sell	-85,607	Closed	-$4.89M	–	1960
2021 Q1	$4.89M	Sell	85,607 -44,232	-34%	-$2.96M	0.01%	1184
2020 Q4	$10.9M	Buy	129,839 +74,368	+134%	+$4.5M	0.02%	848
2020 Q3	$1.99M	Buy	+55,471	New	+$1.67M	﹤0.01%	1555
2020 Q1	–	Sell	-33,242	Closed	-$579K	–	1922
2019 Q4	$579K	Buy	+33,242	New	+$553K	﹤0.01%	1469
2019 Q2	–	Sell	-50,333	Closed	-$1.17M	–	1455
2019 Q1	$1.17M	Buy	+50,333	New	+$1.05M	﹤0.01%	1276

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Arrowstreet Capital's DNLI Position: Q4 2022 in Review

Arrowstreet Capital sold out of Denali Therapeutics (DNLI) in Q4 2022, closing a stake of 18,725 shares — an estimated $575K sold.

Arrowstreet Capital first reported a position in DNLI in Q1 2019 and held it in 7 quarters. The position peaked at $10.9M in Q4 2020. 197 funds tracked by Wall St. Rank hold DNLI as of Q4 2022.

Arrowstreet Capital reported no remaining Denali Therapeutics position as of Q4 2022 after selling out during the quarter.
Arrowstreet Capital sold 18,725 Denali Therapeutics shares in Q4 2022, an estimated $575K.
Arrowstreet Capital first reported a position in Denali Therapeutics in Q1 2019 and held it in 7 quarters.
Arrowstreet Capital's Denali Therapeutics position peaked at $10.9M in Q4 2020.
197 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2022.

Based on Arrowstreet Capital's 13F filing for Q4 2022, filed 14 Feb 2023.